Merit Medical Systems Inc

Day range

$92.77 – $93.87

Open

$93.57

Prev close

$93.94

Volume

750.69K

Market cap

$5.61B

Shares out

59.71M

P/E

38.54

P/S

3.55

P/B

3.34

P/FCF

27.60

ROE

8.7%

ROA

5.1%

Debt/Equity

0.44

Div yield

0.00%

As of Oct 22, 2026

• Executive leadershipAug 20, 2026

  On August 14, 2026, Merit Medical Systems, Inc. reorganized portions of its global operations function. As a result of such reorganization, the position of Chief Operating Officer was eliminated, and Neil W. Peterson's title was changed to Senior Advisor. On August 18, 2026, Mr. Peterson provided Merit with written notice of his resignation for good reason as an employee of the Company effective March 5, 2027.

• Guidance and outlookJul 30, 2026

  Press Release, dated July 30, 2026, entitled 'Merit Medical Reports Second Quarter 2026 Results and Updates Full-Year 2026 Guidance' including unaudited financial information.

• Governance documentsMay 19, 2026

  On May 14, 2026, the Board approved and adopted the Fifth Amended and Restated Bylaws of the Company. Among other things, the Fifth A&R Bylaws: Clarify the ability of shareholders and proxyholders to attend and participate in shareholder meetings by means of remote communication equipment; Permit delivery of notice of shareholder meetings by electronic communication; Clarify the ability of directors to participate in Board meetings by means of remote communication equipment; Update provisions relating to the 'universal proxy' rules under Rule 14a-19 of the Securities Exchange Act of 1934.

• Guidance and outlookApr 30, 2026

  Press Release, dated April 30, 2026, entitled 'Merit Medical Reports First Quarter 2026 Results and Updates Full-Year Guidance' including unaudited financial information.

• Investor communicationsApr 13, 2026

  Merit is providing this historical revenue information for the purpose of aiding period-over-period comparisons for the years and three-month periods indicated. Merit's revenue under the new product categories for the years ended December 31, 2025, 2024, 2023 and 2022, respectively, was as follows... Merit's revenue under the new product categories for the three-month periods ended March 31, June 30, September 30, and December 31, 2025, compared to the corresponding periods of 2024.

• AMNAMN Healthcare Services+2.54%
• ITGRInteger Holdings Corporation-0.02%
• MEDPMedpace Holdings, Inc. Common Stock+2.33%
• WSTWest Pharmaceutical Services, Inc.-0.48%
• ADUSAddus HomeCare Corp.-0.70%
• ELVElevance Health, Inc.-1.20%
• NVSTEnvista Holdings Corporation Common stock, $0.01 par value per share-1.54%
• HQYHealthEquity, Inc+2.97%

Days to cover

6.2

Short interest

3.63M

Avg volume

581.92K

As of Sep 30, 2026 · reported to FINRA twice monthly.

• SOLV Wins FDA Clearance to Combine Restrata Matrix With V.A.C.Therapy
  positiveZacks Investment Research· Oct 23, 2026
• GEHC Expands Theranostics Imaging With 5 Global Collaborations
  positiveZacks Investment Research· Oct 22, 2026
• BD's Revello Stent Shows Strong AGILITY Trial Results for PAD Patients
  positiveZacks Investment Research· Oct 15, 2026
• Doximity Deepens U.S. News Alliance to Improve Patient Access to Care
  neutralZacks Investment Research· Oct 15, 2026
• Glaukos Stock Gains 36.8% in 6 Months: What's Behind the Rally?
  positiveZacks Investment Research· Oct 14, 2026